Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29743628 | 1.00 | ERN1 (0.44) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL30975366 | 0.83 | ERN1 (0.46) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL566230 | 0.83 | ERN1 (0.46) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL29504018 | 0.82 | ERN1 (0.42) | ERN1 | |
| SCHEMBL1418396 | 0.82 | ERN1 (0.42) | ERN1 | |
| SCHEMBL18873290 | 0.82 | ERN1 (0.47) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL27621299 | 0.80 | ERN1 (0.50) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL2371278 | 0.78 | ERN1 (0.47) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL658249 | 0.78 | CYP2C9 (0.41) | ERN1 | |
| SCHEMBL29471351 | 0.78 | CYP2C9 (0.41) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12404286-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | BORAH, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240352045-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| CN-101896486-A | Spiroindolinone derivatives | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | ERN1 829/4885KDM4E 670/4885PTGS2 2035/4885 |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | ERN1 1139/4885KDM4E 1548/4885PTGS2 1882/4885 |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | ERN1 761/4885KDM4E 769/4885PTGS2 4013/4885 |
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | ERN1 2608/4885KDM4E 2534/4885PTGS2 2194/4885 |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | HCN1, HCN4, CRH | ERN1 2728/4885KDM4E 2299/4885PTGS2 3482/4885 |
| US-20240352045-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | ERN1 1139/4885KDM4E 1548/4885PTGS2 1882/4885 |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | EGFR, ERBB2, ERBB3 | ERN1 1399/4885KDM4E 169/4885PTGS2 4335/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | ERN1 1523/4885KDM4E 444/4885PTGS2 2199/4885 |
| US-12404286-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | JAK3, JAK1, JAK2 | ERN1 1139/4885KDM4E 1548/4885PTGS2 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.